LEXICON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $195.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-03-05
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was $195.00K, a 57.05% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $454.00K, a 22.53% decline from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $586.00K, a 146.22% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was $238.00K, a 35.33% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month |
|---|---|
| 2025-12-31 | $195.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $454.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $586.00K 10-K · filed 2026-03-05 |
| 2022-12-31 | $238.00K 10-K · filed 2025-03-07 |
| 2021-12-31 | $368.00K 10-K · filed 2024-03-25 |
| 2020-12-31 | $157.00K 10-K · filed 2023-03-03 |
| 2019-12-31 | $1.06M 10-K · filed 2022-03-10 |
| 2018-12-31 | $115.00K 10-K · filed 2021-03-12 |
| 2017-12-31 | -$372.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |